WARNING: Severe liver injury and acute liver failure, in some cases fatal, have been reported in patients treated with propylthiouracil. These reports of hepatic reactions include cases requiring liver transplantation in adult and pediatric patients.
Propylthiouracil should be reserved for patients who can not tolerate methimazole and in whom radioactive iodine therapy or surgery are not appropriate treatments for the management of hyperthyroidism.
Because of the risk of fetal abnormalities associated with methimazole, proplythiouracil may be the treatment of choice when an antithyroid drug is indicated during or just prior to the first trimester of pregnancy (see Warnings and Precautions).
Propylthiouracil (6-propyl-2-thiouracil) is one of the thiocarbamide compounds. It is a white, crystalline substance that has a bitter taste and is very slightly soluble in water.
Propylthiouracil is an antithyroid drug administered orally.
Propylthiouracil is indicated:
- in patients with Graves' disease with hyperthyroidism or toxic multinodular goiter who are intolerant of methimazole and for whom surgery or radioactive iodine therapy is not an appropriate treatment option.
- to ameliorate symptoms of hyperthyroidism in preparation for thyroidectomy or radioactive iodine therapy in patients who are intolerant of methimazole.
Published Studies Related to Propylthiouracil
Greater energy intake from a buffet meal in lean, young women is associated with the 6-n-propylthiouracil (PROP) non-taster phenotype. [2011.02]
Taste blindness to 6-n-propylthiouracil (PROP) is a common phenotype that has been associated with increased adiposity in women, and might be linked to increased selection of dietary fats. Since exposure to a variety of high-fat/energy-dense foods is known to promote excess energy intake, we investigated if PROP non-taster women would consume more fat and/or energy in a buffet setting than super-taster women.
Effects of short-term propylthiouracil treatment on p wave duration and p wave dispersion in patients with overt hypertyroidism. [2007.06]
CONCLUSION: P wave duration and PWD are found prolonged in hyperthyroid patients and propylthiouracil treatment decreased them effectively. This mechanism may establish how the anti-thyroid treatment may prevent the development of atrial fibrillation in hyperthyroid patients.
Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease. [2007.06]
CONTEXT: Although methimazole (MMI) and propylthiouracil (PTU) have long been used to treat hyperthyroidism caused by Graves' disease (GD), there is still no clear conclusion about the choice of drug or appropriate initial doses. OBJECTIVE: The aim of the study was to compare the MMI 30 mg/d treatment with the PTU 300 mg/d and MMI 15 mg/d treatment in terms of efficacy and adverse reactions... CONCLUSIONS: MMI 15 mg/d is suitable for mild and moderate GD, whereas MMI 30 mg/d is advisable for severe cases. PTU is not recommended for initial use.
The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves' hyperthyroidism. [2005.05]
OBJECTIVE: The study aims to evaluate the efficacy of combination therapy with propylthiouracil (PTU) and cholestyramine in the treatment of Graves' hyperthyroidism. BACKGROUND: Thyroxine (T4) is metabolized mainly in the liver by conjugation to glucuronides and sulphates that enter the enterohepatic circulation. Thyrotoxic patients have an abnormal increase in thyroid hormone in their enterohepatic circulation. Previous studies on combination therapy with methimazole and cholestyramine for Graves' hyperthyroidism have shown it to be an effective adjunctive treatment. In this study, we examined the efficacy of combination therapy with PTU and cholestyramine in the treatment of Graves' hyperthyroidism... CONCLUSION: Cholestyramine contributed to a more rapid and complete decline in thyroid hormone levels in patients with Graves' hyperthyroidism. It was thus proved to be an effective and well-tolerated adjunctive therapy.
Propylthiouracil before 131I therapy of hyperthyroid diseases: effect on cure rate evaluated by a randomized clinical trial. [2004.09]
A randomized clinical trial was performed to clarify whether pretreatment with propylthiouracil (PTU) before radioiodine ((131)I) therapy influences the final outcome of this therapy, as has been indicated by retrospective studies. Untreated consecutive hyperthyroid patients with Graves' disease (n = 23) or a toxic nodular goiter (n = 57) were randomized to either PTU (+PTU; n = 39) or no pretreatment (-PTU; n = 41) before compensated (131)I therapy...
Clinical Trials Related to Propylthiouracil
Antithyroid Drug Treatment of Thyrotoxicosis in Young People [Recruiting]
The investigators aim to establish whether the remission rates following anti-thyroid drug
therapy in young people with thyrotoxicosis are affected by treatment with a 'block and
replace' or 'dose titration' regimen. This will be determined by assessing the proportion of
individuals with normal thyroid function off anti-thyroid drug therapy at the end of the of
the study period. The investigators shall also assess biochemical stability and the
frequency of side-effects to tthe anti-thyroid drug.
The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy [Recruiting]
The relationship between the method of the treatment of hyperthyroidism due to Graves'
disease and the course of Graves' ophthalmopathy is debated. The investigators aimed to
compare the results of total thyroidectomy done in 6 months following the appearance of the
symptoms of ophthalmopathy and the antithyroid drug therapy in patients with moderate to
severe Graves' ophthalmopathy.
The inclusion criteria: 1)Hyperthyroidism and moderate to severe Graves' ophthalmopathy
within 6 months, 2)Thyroid volumes greater than or equal to 15 mL in thyroid
ultrasonography, 3)Patients taking no treatment except local medications for Graves'
ophthalmopathy, 4)Clinical activity score of 3/7 or more, proptosis greater than or equal to
21 mm in one eye or 2 mm difference between two eyes, presence of diplopia, the opening of
the eye lid greater than or equal to 9 mm.
All patients will be treated with antithyroid drug until TSH levels of the patients are
between 0. 4-1. During this period all the patients will take pulse methyl prednisolone
treatment of a total dose of 4. 5 gr. After pulse steroid treatment the patients will be
randomised to two groups: one group will be sent to surgery for total thyroidectomy, and
their TSH levels will be kept between 0. 4-1 with levothyroxine treatment; the other group
will be followed under antithyroid drug treatment and their TSH levels will be kept between
0. 4-1 also.
The smoking habits will be asked. Serum TSH, fT4 levels, Hertelmeter and eye lid opening
measurements, clinical activity scores, diplopia will be evaluated monthly; TSH receptor
antibody, anti-thyroid peroxidase and anti-thyroglobulin levels will be measured in 3 months
intervals for a period of 12 months.
Computer Based Intervention for Type 2 Diabetes in Youth [Recruiting]
Interactive multimedia programs have been demonstrated to produce substantial change in
children's dietary behaviors. This SBIR-Phase 2 protocol will evaluate the two video game
interventions designed to change diabetes related behaviors, including diet and physical
activity: Escape from Diab! and Nanoswarm that were developed in Phase 1. The primary
hypotheses for this SBIR-Phase 2 protocol are:
1. The two video games will result in greater dietary and physical activity change than a
knowledge based control group.
2. The effects of the video games will be mediated by changes in child preferences for FV
and PA, self-efficacy to change FV intake and PA, and intrinsic motivation to eat FV
We will test these hypotheses by evaluating the two video games in a randomized experiment.
To minimize costs, we will evaluate the impact of the games on behavior (diet and PA), BMI
and related psychosocial variables, but not blood values. Our long-term goal is reducing the
incidence of Type 2 diabetes and related health problems in youth.
Reports of Suspected Propylthiouracil Side Effects
Weight Decreased (2),
Head Circumference Abnormal (2),
Foetal Exposure During Pregnancy (2),
Cerebral Haemorrhage (2),
Foetal Distress Syndrome (2), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 1 ratings/reviews, Propylthiouracil has an overall score of 7. The effectiveness score is 6 and the side effect score is 6. The scores are on ten point scale: 10 - best, 1 - worst.
Propylthiouracil review by 43 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Moderately Effective|
|Side effects:|| || Moderate Side Effects|
|Condition / reason:|| || Hyperthyroid - Graves Disease|
|Dosage & duration:|| || 150 - 450 mcg (dosage frequency: 3 times per day) for the period of 2 years|
|Other conditions:|| || None|
|Other drugs taken:|| || None|
|Benefits:|| || Reduced the level of thyroid hormone, thereby minimizing many of the hyperthyroid symptoms. |
|Side effects:|| || Muscle cramps.|
|Comments:|| || PTU was administered in varying doses while thyroid hormone levels were monitored. The dose was adjusted accordingly, but often the response was a few weeks behind the dosage change, hence it was difficult to titer and keep hormone levels within normal ranges.|
Page last updated: 2011-12-09